FDA 483 - Mihalko Medical, LLC - July 17, 2019

This FDA Form 483 document outlines observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed four key deficiencies related to quality systems and manufacturing controls.

Observation 1 indicates the firm failed to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This suggests a potential risk to product sterility and patient safety, as environmental controls are critical in aseptic manufacturing to prevent contamination.

Observation 2 notes that the firm did not adequately validate the sterilization process for production equipment. Proper validation ensures that equipment is consistently sterilized to eliminate microbial contamination, which is a fundamental requirement for sterile product manufacturing.

Observation 3 identifies that the firm did not conduct routine calibration of critical manufacturing equipment. Uncalibrated equipment can lead to inaccurate measurements and process deviations, potentially affecting product quality, potency, and purity.

Observation 4 states that the firm lacked proper documentation for the training of personnel involved in the manufacturing process. Adequate and documented training is essential to ensure that personnel possess the necessary skills and knowledge to perform their duties correctly and in compliance with Good Manufacturing Practices (GMP).

These observations collectively point to significant gaps in the firm's quality management system, particularly concerning environmental control, process validation, equipment maintenance, and personnel training. Addressing these deficiencies is crucial for the firm to ensure product quality, safety, and regulatory compliance.